Physician profile
Suzanne A Beck
NPI 1861597973
$3,365.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $255 · 2021: $1,042 · 2022: $693.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $750.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $723.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $263.96 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $239.09 | 2019-2021 | |
| Amgen INC. | $210.22 | 2021-2022 | |
| Genzyme Corporation | $167.21 | 2019-2022 | |
| Abbvie INC. | $119.51 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.11 | 2020-2021 | |
| Mylan Specialty L.P. | $118.67 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $107.94 | 2019 | |
| Pharming Healthcare, INC. | $90.96 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $83.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $62.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.16 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $49.89 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.07 | 2019-2022 | |
| Optinose US, INC. | $25.17 | 2022 | |
| Grifols USA, LLC | $19.96 | 2021 | |
| Kaleo, INC. | $18.85 | 2019 | |
| Lilly USA, LLC | $18.37 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.06 | 2022 | |
| Shire North American Group INC | $16.97 | 2019 | |
| Genentech USA, INC. | $16.43 | 2021 | |
| Csl Behring | $14.72 | 2022 | |
| Aimmune Therapeutics, INC. | $14.26 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.